Page last updated: 2024-08-21

oxazoles and Fatty Liver

oxazoles has been researched along with Fatty Liver in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (20.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bennett, M; Charlton, M; Chung, C; Harrison, SA; Harting, E; Kayali, Z; Lai, M; Lawitz, EJ; Loomba, R; McColgan, BJ; Middleton, MS; Myers, RP; Noureddin, M; Ray, AS; Ruane, P; Subramanian, GM; Tarrant, JM; Wang, L	1
Anthérieu, S; Claude, N; de la Moureyre-Spire, C; Guillouzo, A; Rogue, A; Umbdenstock, T; Vluggens, A; Weaver, RJ	1
Chen, CT; Cheng, JT; Chi, CW; Chung, HH; Wu, HT; Yang, PS; Yeh, CH	1
Moseley, RH	1
Sickinger, K	1

Trials

1 trial(s) available for oxazoles and Fatty Liver

Article	Year
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, Volume: 155, Issue:5 Topics: Acetyl-CoA Carboxylase; Biomarkers; Carnitine; Double-Blind Method; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Isobutyrates; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxazoles; Pyrimidines	2018

Article

Year

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.

Gastroenterology, 2018, Volume: 155, Issue:5

Topics: Acetyl-CoA Carboxylase; Biomarkers; Carnitine; Double-Blind Method; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Isobutyrates; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxazoles; Pyrimidines

2018

Other Studies

4 other study(ies) available for oxazoles and Fatty Liver

Article	Year
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicology and applied pharmacology, 2014, Apr-01, Volume: 276, Issue:1 Topics: Cell Line; Constitutive Androstane Receptor; Drug Evaluation, Preclinical; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Glycine; Humans; Lipid Metabolism; Lipogenesis; Lipotropic Agents; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Oleic Acid; Orphan Nuclear Receptors; Oxazoles; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Triglycerides	2014
Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:1 Topics: Animals; Calcium; Cell Line, Tumor; Diet, High-Fat; Egtazic Acid; Fatty Liver; Humans; Imidazoline Receptors; Lipid Metabolism; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Oleic Acid; Oxazoles; Receptors, Cytoplasmic and Nuclear; Rilmenidine	2012
Therapy for nonalcoholic fatty liver disease. Journal of clinical gastroenterology, 2008, Volume: 42, Issue:4 Topics: Animals; Antioxidants; Cholagogues and Choleretics; Disease Models, Animal; Fatty Liver; Glycine; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Mice; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rats; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E	2008
[Necessity of glucose for long term blockade of the lipolysis with 3,5-dimethylisoxazole and 5-methylpyrazole-3-carboxylic acid]. Klinische Wochenschrift, 1968, May-15, Volume: 46, Issue:10 Topics: Animals; Blood Glucose; Ethanol; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Glucose; Glycerol; Injections, Intravenous; Lipid Metabolism; Lipids; Liver; Oxazoles; Pyrazoles; Rats	1968